Lilly's EBGLYSS Monotherapy Met Primary And Secondary Endpoints At Week 16 In Its Phase 3B ADtouch Study, Showing Significant And Rapid Improvements In Hand And Foot Skin Clearance, Itch And Pain In Adults And Adolescents With Moderate-To-Severe Hand And Foot Atopic Dermatitis

Loading news article.

Lilly's EBGLYSS Monotherapy Met Primary And Secondary Endpoints At Week 16 In Its Phase 3B ADtouch Study, Showing Significant And Rapid Improvements In Hand And Foot Skin Clearance, Itch And Pain In Adults And Adolescents With Moderate-To-Severe Hand And Foot Atopic Dermatitis | WAPE

Lilly's EBGLYSS Monotherapy Met Primary And Secondary Endpoints At Week 16 In Its Phase 3B ADtouch Study, Showing Significant And Rapid Improvements In Hand And Foot Skin Clearance, Itch And Pain In Adults And Adolescents With Moderate-To-Severe Hand And Foot Atopic Dermatitis

Article summary

Related companies

Comments —